Related Experiment Videos
Spontaneous echo contrast: where there's smoke there's fire
1Department of Cardiology, Manly Hospital, Darley Road, Manly NSW 2095, Australia.
Echocardiography (Mount Kisco, N.Y.)
|September 9, 2000
Summary
Left atrial spontaneous echo contrast (SEC), detected via echocardiography, indicates a hypercoagulable state and predicts embolic events. Early detection and anticoagulation are crucial for managing patients with atrial fibrillation or mitral stenosis.
Area of Science:
- Cardiology
- Hematology
- Medical Imaging
Background:
- Left atrial spontaneous echo contrast (LA SEC), or "smoke," is a common echocardiographic finding, typically seen on transesophageal echocardiography (TEE) but rarely on transthoracic echocardiography (TTE).
- LA SEC is characterized by dynamic, smoke-like echoes within the left atrium (LA) or its appendage.
- It is frequently associated with conditions promoting LA stasis, such as atrial arrhythmias, mitral stenosis, mitral valve prosthesis, and enlarged LA, while mitral regurgitation appears protective.
Purpose of the Study:
- To elucidate the clinical significance and underlying mechanisms of LA SEC.
- To explore the prognostic value of LA SEC in various cardiovascular conditions.
- To guide therapeutic strategies, particularly anticoagulation, for patients with LA SEC.
Main Methods:
- Review of echocardiographic findings, specifically LA SEC on TEE and TTE.
- Correlation of LA SEC presence with patient conditions (atrial arrhythmias, mitral valve disease, LA size, thrombus).
- Analysis of hematological factors and red blood cell aggregation dynamics contributing to LA SEC.
Main Results:
- LA SEC is strongly associated with LA thrombus and a history of embolic events.
- In nonvalvular atrial fibrillation, LA SEC predicts future embolism and mortality.
- LA SEC is a marker of a hypercoagulable state, resulting from red blood cell aggregation at low shear rates, independent of platelets.
Conclusions:
- LA SEC is a significant indicator of thromboembolic risk, especially in nonvalvular atrial fibrillation.
- Its presence warrants consideration for anticoagulant therapy and management of underlying cardiovascular issues.
- Further research into quantification, prognostic assessment in low-risk patients, and novel treatments is warranted.